Breakthrough in Cancer Immunotherapy: Researchers Develop Integrated System for Screening Tumor-Specific T-Cell Receptors

Strategic Insights -

Researchers at Kunming Medical University have made a significant discovery in the field of cancer immunotherapy, developing an integrated system for screening tumor-specific T-cell receptors (TCRs). According to the study, published in the Journal for ImmunoTherapy of Cancer, the system enables the rapid assembly and construction of TCR libraries, significantly accelerating the process and reducing costs.

The integrated system, which includes an antigen-presenting cell line, a TCR assembly method, and a TCR reporter cell line, was validated through a small-scale screening of HPV16-specific TCRs from patients with cervical cancer. The researchers successfully isolated a human papillomavirus (HPV)-specific TCR using the system, demonstrating its potential for efficient screening of tumor-specific TCRs.

Key Takeaways:

  • Researchers at Kunming Medical University developed an integrated system for screening tumor-specific T-cell receptors (TCRs) using single-cell sequencing data.
  • The system includes an antigen-presenting cell line, a TCR assembly method, and a TCR reporter cell line.
  • The system was validated through a small-scale screening of HPV16-specific TCRs from patients with cervical cancer.
  • The researchers successfully isolated a human papillomavirus (HPV)-specific TCR using the system.
  • The integrated system has the potential to advance TCR-T immunotherapy by efficiently screening tumor-specific TCRs.
  • The system's efficacy was demonstrated through the identification of a functional, HPV-specific TCR.

Statistics:

  • The integrated system enables the rapid assembly and construction of TCR libraries in 2 days, significantly accelerating the process.
  • The system reduces costs associated with TCR screening.
  • The researchers successfully isolated a human papillomavirus (HPV)-specific TCR using the system.
  • The study demonstrates the system's potential for efficient screening of tumor-specific TCRs in cancer therapy.

Sources:

  • Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data. Journal for ImmunoTherapy of Cancer, 2025, 13(7).
  • NewsRx. Data on Cancer Detailed by Researchers at Kunming Medical University (Integrated system for screening tumor-specific TCRs, epitopes, and HLA subtypes using single-cell sequencing data). Immunotherapy Weekly. August 20, 2025; p 150.